

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on Unaudited Consolidated Financial Results of Advanced Enzyme Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Advanced Enzyme Technologies Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of Advanced Enzyme Technologies Limited ('the Company') and its subsidiaries listed in Annexure 1 (collectively referred to as 'the Group'), for the quarter ended 30 June 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the 3 months ended 31 March 2018 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these consolidated financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the financial information of two subsidiaries included in the statement of unaudited consolidated financial results and consolidated year-to-date financial results, whose unaudited financial information reflect total revenue of Rs 234 million for the quarter ended 30 June 2018 and total assets of Rs. 742 million as at 30 June 2018. This unaudited financial information has been reviewed by other auditors whose reports have been furnished to us, and our opinion on the unaudited consolidated financial results and the year-to-date results, to the extent they have been derived from such unaudited financial information is based solely on the report of such other auditors. Our conclusion is not modified in respect of such matter.



**Limited Review Report on Unaudited Consolidated Financial Results of
Advanced Enzyme Technologies Limited pursuant to the Regulation 33 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
(Continued)**

Advanced Enzyme Technologies Limited

The accompanying statement includes the interim financial results of four subsidiaries whose interim financial information reflect total revenues of Rs. 67 million for the quarter ended 30 June 2018 and total assets of Rs. 816 million as at 30 June 2018, which have not been subjected to limited review by their auditors. These interim financial results have been certified by the Company's management and our report on the Statement, in so far as it relates to the amounts included in respect of these entities, is based solely on such interim financial results certified by the Company's management. In our opinion and according to the information and explanations given to us by the Company's management, these financial results are not material to the Group. Our conclusion is not modified in respect of such matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022



Sadashiv Shetty
Partner
Membership No: 048648

Mumbai
11 August 2018

Advanced Enzyme Technologies Limited

Annexure I

The unaudited consolidated financial results include the results of the following entities:

Sr. No.	Name of entity	Relationship as at 31 March 2018	Country of incorporation
1	Advanced-Bio Agro Tech Limited	Subsidiary (60%)	India
2	Advanced Enzytech Solutions Limited	Wholly owned subsidiary	India
3	Advanced Enzymes USA, Inc.	Wholly owned subsidiary	U.S.A
4	Cal India Foods International	Wholly owned subsidiary of Advanced Enzymes USA, Inc.	U.S.A
5	Advanced Supplementary Technologies Corporation	Wholly owned subsidiary of Advanced Enzymes USA, Inc.	U.S.A
6	Enzyme Innovation, Inc.	Wholly owned subsidiary of Cal India Foods International	U.S.A
7	Dynamic Enzymes, Inc.	Wholly owned subsidiary of Advanced Enzymes USA, Inc.	U.S.A
8	Enzyfuel Innovation, Inc. (Upto 18 September 2017)	Wholly owned subsidiary of Advanced Enzymes USA, Inc.	U.S.A
9	JC Biotech Private Limited (Acquired on 1 December 2016)	Subsidiary (70%)	India
10	Advanced Enzymes (Malaysia) Sdn. Bhd (Acquired on 3 July 2017)	Wholly owned subsidiary	Malaysia
11	Advanced Enzymes Europe B.V. (Incorporated on 11 July 2017)	Wholly owned subsidiary	Netherlands
12	Evovx Technologies GmbH (Acquired on 15 August 2017)	Wholly owned subsidiary of Advanced Enzymes Europe B.V.	Germany

Statement of unaudited consolidated financial results for the quarter ended June 30, 2018

(₹ in million except per share data)

Particulars	Quarter ended		Year ended	
	30th June 2018 Unaudited	31st March 2018 Audited (refer note ix)	30th June 2017 Unaudited	31st March 2018 Audited
1 Revenue from operations (refer note iii)	1,042.83	1,086.28	801.62	3,956.99
2 Other income	3.78	5.64	3.21	13.94
3 Total income (1+2)	1,046.61	1,091.92	804.83	3,970.93
4 Expenses				
(a) Cost of materials consumed	230.42	226.42	176.21	799.37
(b) Purchases of stock-in-trade	0.24	2.68	0.74	3.91
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-59.60	-43.96	-26.44	11.44
(d) Excise duty	-	-	46.84	46.84
(e) Employee benefits expense	201.45	190.23	149.94	685.95
(f) Finance costs	13.72	45.02	13.48	80.86
(g) Depreciation and amortisation expense	51.83	47.12	37.55	182.98
(h) Other expenses	186.71	226.92	158.77	769.91
Total Expenses	624.77	694.43	557.09	2,581.26
5 Profit before exceptional item and tax (3-4)	421.84	397.49	247.74	1,389.67
6 Exceptional item	-	-	-	-
7 Profit before tax (5-6)	421.84	397.49	247.74	1,389.67
8 Tax expenses				
Current tax	122.48	137.25	77.60	461.82
Deferred tax charge / (credit)	-12.96	-23.15	7.47	-7.71
Total tax expense	109.52	114.10	85.07	454.11
9 Net profit for the period (7-8)	312.32	283.39	162.67	935.56
10 Other comprehensive income:				
A (i) Items that will not be reclassified to Statement of profit and loss	-0.15	1.74	-5.04	-0.91
(ii) Income tax related to items that will not be reclassified to Statement of profit and loss	0.26	-0.81	1.70	0.09
B (i) Items that will be reclassified to Statement of profit and loss	149.84	104.50	-	79.68
(ii) Income tax related to items that will be reclassified to Statement of profit and loss	-	-	-	-
Total Other comprehensive Income	149.95	105.43	-3.34	78.86
11 Total comprehensive income (9+10)	462.27	388.82	159.33	1,014.40
12 Net profit attributable to:				
Shareholders of the Company	296.65	272.43	157.78	900.55
Non-controlling interest	15.67	10.96	4.89	35.01
13 Other comprehensive income attributable to:				
Shareholders of the Company	150.15	106.33	-3.30	79.87
Non-controlling interest	-0.20	-0.90	-0.04	-1.01
14 Total comprehensive income attributable to:				
Shareholders of the Company	446.80	378.76	154.48	980.41
Non-controlling interest	15.47	10.06	4.85	34.00
15 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.30	223.26	223.26	223.26
16 Other equity	-	-	-	5,367.55
17 Earnings Per Share of ₹ 2 each (not annualized)				
(a) ₹ (Basic)	2.66	2.44	1.46	8.07
(b) ₹ (Diluted)	2.66	2.43	1.46	8.06



Notes:

(i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India) (w.e.f. 1 December 2016), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.), Enzyfuel Innovation, Inc. (U.S.A.) (up to 18 September 2017), Advanced Enzymes (Malaysia) Sdn Bhd. (Malaysia) (w.e.f. 3 July 2017), Advanced Enzymes Europe B.V. (Netherlands) (w.e.f. 11 July 2017) and Evoox Technologies GmbH (Germany) (w.e.f. 15 August 2017). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above unaudited consolidated financial results for the quarter ended 30 June 2018 of Advanced Enzyme Technologies Limited (the Company) were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 11 August 2018. The statutory auditors of the Company have carried out limited review of the above unaudited consolidated financial results pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Limited Review report does not have any qualifications. The Limited Review report will be filed with stock exchanges and will be available on the Company's website.

(iii) According to the requirements of Ind AS and SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, revenue for the corresponding previous quarter ended 30 June 2017 and the year ended 31 March 2018 were and are reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax ("GST") from 1 July 2017, replacing Excise Duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the quarters ended 30 June 2018 and 31 March 2018 and year ended 31 March 2018 are reported net of GST. Had the previously reported revenues were shown net of Excise Duty, comparative revenue of the Company would have been as follows:

Particulars	(₹ in Million)		
	Quarter ended		Growth %
	30 June 2018	30 June 2017	
Revenue from operations	1,042.83	756.33	38%

(iv) The Group operates only in one primary business segment viz 'manufacturing and sales of enzymes'.

(v) The results include the financial results of wholly owned subsidiary, Advanced Enzymes Europe B.V., Netherlands, incorporated on 11 July 2017, wholly owned subsidiary Advanced Enzymes (Malaysia) Sdn Bhd acquired on 3 July 2017 and step-down wholly owned subsidiary Evoox Technologies GmbH (Evoox), Germany, acquired on 15 August 2017 and hence the figures for the quarter ended 30 June 2018 are not comparable with the previous corresponding period.

(vi) The Board of Directors in their meeting held on 19 May 2018 have proposed the final dividend for the financial year 2017-18 of Rs 0.50 per equity share and the same will be paid after approval of Shareholders in the Annual General Meeting of the Company.

(vii) Effective 1 April 2018, the Company and its subsidiaries have adopted Ind AS 115 'Revenue from Contracts with Customers'. Based on the assessment done by management, there is no material impact on the revenue recognised.

(viii) During the quarter, the Company has allotted 18,800 equity shares to employees under the 'AETL Employee Stock Option Scheme 2015' ('AETL ESOS 2015').

(ix) The figures for the quarter ended 31 March 2018 as reported in these unaudited consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.

By Order of the Board of Directors
For Advanced Enzyme Technologies Limited



C.L. Rathi
Managing Director
DIN : 00365691



Place Thane
Dated: 11 August 2018

